VVOS Vivos Therapeutics, Inc.

NASDAQ
$0.06

Vivos Therapeutics, Inc. (VVOS) is expected to report earnings on February 15, 2027, after the market close. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.2% since its last earnings release on November 16, 2026.

Vivos Therapeutics Beat Consensus Estimates
Monday, November 16, 2026 · 6:31 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 15
Monday · After Close
Earnings Whisper
-
vs ($0.20)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.08

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vivos Therapeutics, Inc.

Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA).

Sector

Healthcare

Industry

Medical Appliances/Equipment

Charts powered in part by Lightweight Charts™ by TradingView.